Kenvue (NYSE: KVUE) has been volatile the past seven days following President Trump’s call to ban Tylenol, its flagship medication brand.

On September 22, Trump told pregnant women to avoid Tylenol, claiming that prenatal use of acetaminophen could raise autism risk. 

His comments drew sharp criticism from medical experts and health authorities worldwide, putting renewed scrutiny on Kenvue, which took the medicine over in its 2023 spin-off from Johnson & Johnson (NYSE: JNJ).

Since the beginning of the controversy and Trump’s initial warning, the company’s stock has dropped 3.71%, trading at $16.34 at the time of writing, down from $16.97 on September 22 .

Interestingly, though, the majority of the decline in KVUE stock price came before the President’s announcement with Kenvue shares now down 21.37% on the monthly chart, having fallen from their 30-day peak of $20.78 on September 2. 

Tylenol maker insider trading controversy

Further contributing to the uncertainty, three U.S. lawmakers sold shares in the healthcare company shortly before Trump made his comments. 

Namely, Senator Sheldon Whitehouse disclosed selling his entire stake, valued between $1,001 and $15,000, on August 28, 2025, while Representative Ro Khanna offloaded shares in the same range just two days earlier. 

Representative Scott Franklin made a similar sale a bit earlier, on June 16, through a joint account with his wife.

The timing of the three politicians’ sales has naturally raised concerns regarding potential conflicts of interest, although there is currently no evidence that the lawmakers acted on insider information. 

What’s more, the trades highlight ongoing concerns over lawmakers’ stock activity, as bipartisan attempts to ban stock trading outright have repeatedly stalled this year even amid high-profile scandals and controversies involving even the most vocal proponents of the ban, such as the aforementioned Ro Khanna, who has made over 34,000 trades since he was elected in 2017.

Featured image via Shutterstock